Phenol as OTC antitussive
Results of five clinical studies to support adding phenol to the antitussive final monograph, published in August 1988, have been submitted by Rich-Vicks to FDA. Phenol is the active ingredient in the company's Chloraseptic. The ingredient is a Category I anesthetic/analgesic, but is not included in the antitussive monograph. The petition maintains that although no data had been submitted, Chloraseptic has been labeled for "smokers cough" dating back to the 1960s.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.